Creative Biolabs has announced the launch of an integrated, one-stop antisense oligonucleotide (ASO) development services platform designed to address key technical bottlenecks in RNA therapeutics. As ASO development often faces challenges such as designing candidates with high binding affinity, overcoming in vivo enzymatic degradation, and achieving tissue-specific delivery, this new platform aims to bridge these gaps and accelerate pipeline progression.
The platform combines advanced bioinformatics, chemical synthesis, and rigorous preclinical validation to support global biotechnology companies and academic institutions. Traditional ASO development is often fragmented, requiring researchers to coordinate with multiple vendors for design, synthesis, and animal testing, leading to extended timelines and data inconsistency. Creative Biolabs solves this by unifying the entire pipeline under one roof.
Key features of the platform include proprietary bioinformatic optimization using thermodynamic simulation and RNA secondary structure accessibility prediction to identify optimal target regions and mitigate off-target risks. It offers advanced chemical modification and synthesis capabilities, including versatile oligonucleotide architectures such as Gapmers and steric-blocking oligos, with scales ranging from milligram to multi-gram. Modifications like PS backbones, PMO, and sugar modifications (2'-MOE, cEt) improve nuclease resistance and support in vivo stability.
Precision delivery and conjugation technologies solve the cellular uptake barrier through custom targeted delivery, including GalNAc conjugation for liver targeting, Antibody-Oligonucleotide Conjugates (AOCs) for extrahepatic tissues, and specialized LNP formulations. Robust preclinical validation provides data-rich in vitro screening (mRNA knockdown via qPCR, cytotoxicity testing) and in vivo PK/PD profiling to support preclinical candidate selection.
"Many therapeutic pipelines stall because a high-affinity sequence fails under physiological conditions due to poor delivery or low stability," stated the Chief Scientific Officer at Creative Biolabs. "Our one-stop platform eliminates these silos. By matching customized chemical modifications with precise conjugation chemistries early in the design phase, we significantly lower required doses and improve the safety profiles of our clients' candidates."
With a robust portfolio of ready-to-use ASO products spanning oncology, genetic disorders, and neuromuscular diseases, Creative Biolabs provides the flexibility and technical expertise required to turn therapeutic concepts toward preclinical candidate development. The launch of this end-to-end service represents a significant step in streamlining ASO development, potentially reducing time and costs for researchers working on RNA-based therapies.
